Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial

NALA Investigators

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Fingerprint

Dive into the research topics of 'Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial'. Together they form a unique fingerprint.

Medicine & Life Sciences